Addex Therapeutics Ltd (SWX:ADXN)

Addex Therapeutics Cash Flow Statement

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	7.06	-10.56	-20.8	-15.35
Depreciation & Amortization	0.19	0.01	0.01	0.35
Loss (Gain) on Equity Investments	2.18	-	-	-
Stock-Based Compensation	0.18	0.28	0.68	1.34
Other Operating Activities	-0.18	0.29	0.2	-0.28
Change in Accounts Receivable	0.13	0.45	-0.27	-0.26
Change in Accounts Payable	-1.15	-0.61	-0.43	0.88
Change in Unearned Revenue	-0.04	0.32	-	-0.82
Change in Other Net Operating Assets	-0.18	0.06	0.86	-0.57
Operating Cash Flow	-5.37	-7.99	-16.44	-14.71
Capital Expenditures	-0	-0.01	-0	-0.03
Investment in Securities	-	-	0	0
Other Investing Activities	4.65	-	-	-
Investing Cash Flow	4.65	-0.01	0	-0.03
Long-Term Debt Repaid	-0.07	-0.28	-0.29	-0.31
Net Debt Issued (Repaid)	-0.07	-0.28	-0.29	-0.31
Issuance of Common Stock	0.24	2.35	1.68	13.96
Repurchase of Common Stock	-0.03	-0.05	-0.31	-0.39
Other Financing Activities	-0.04	3.24	2.02	3.14
Financing Cash Flow	0.1	5.26	3.1	16.4
Foreign Exchange Rate Adjustments	0.1	-0.36	-0.2	0.12
Net Cash Flow	-0.52	-3.09	-13.53	1.79
Free Cash Flow	-5.37	-8	-16.44	-14.74
Free Cash Flow Margin	-1310.80%	-494.64%	-1137.59%	-467.34%
Free Cash Flow Per Share	-0.06	-0.11	-0.36	-0.43
Cash Interest Paid	0.01	0.02	0.05	0.06
Levered Free Cash Flow	-3.01	-0.99	-6.19	-8.2
Unlevered Free Cash Flow	-3.01	-0.99	-6.17	-8.16
Change in Working Capital	-1.23	0.21	0.16	-0.76

Source: S&P Global Market Intelligence. Standard template. Financial Sources.